Gilead resumed with a Buy at Guggenheim. Guggenheim analyst Whitney Ijem resumed coverage of Gilead Sciences with a Buy rating and $86 price target. With management uncertainty “now moving into the rearview mirror,” the analyst likes the shares heading into 2019. She thinks Gilead’s base business is positioned well and points out the company has several Phase 3 data readouts next year. Ijem calls Selonsertib a “coin-flip” but believes filgotinib data is likely to be positive.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.